S&P: Catalent unchanged

Standard & Poor's said the B+ ratings on Catalent Pharma Solutions and stable outlook remain unchanged following news that the company will acquire the clinical trial supplies business of Aptuit LLC for $410 million.

A portion of this acquisition will be funded with debt that, on a pro forma basis, will increase the company's leverage, S&P said.

But this does not meaningfully affect a perception of the company's highly leveraged financial risk profile, the agency said.

While the acquisition adds some diversity to the company's offering of outsourced services for its pharmaceutical clients, S&P said it does not significantly alter the company's satisfactory business risk profile, particularly given potential integration issues.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.